Previous close | 14.90 |
Open | 14.18 |
Bid | 13.84 x 200 |
Ask | 13.92 x 100 |
Day's range | 13.50 - 14.34 |
52-week range | 10.93 - 28.35 |
Volume | |
Avg. volume | 920,191 |
Market cap | 887.771M |
Beta (5Y monthly) | 1.17 |
PE ratio (TTM) | N/A |
EPS (TTM) | -5.31 |
Earnings date | 06 Aug 2024 - 12 Aug 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 36.36 |
WALTHAM, Mass., May 10, 2024--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that senior management will participate in the following upcoming investor conferences in May:
Viridian Therapeutics ( NASDAQ:VRDN ) First Quarter 2024 Results Key Financial Results Net loss: US$48.5m (loss...
Discover key insights from VRDN's Q1 2024 earnings, including trial successes, financial stability, and future regulatory plans.